Daiichi Sankyo

Ranbaxy buyout boosts Daiichi profit 10-fold

Daiichi Sankyo posted an April-June recurring profit of 70.1 billion yen (USD 808 million), up from ...

The country`s largest drug maker by sales, Ranbaxy Laboratories, today said it would launch Olmesart...

Ranbaxy Laboratories will launch Olmesartan Medoxomil, an anti-hypertensive drug from parent company...

Daiichi Sankyo, which has a majority stake in Ranbaxy Laboratories, today said it is going to laun...

Leading Japanese drug-maker Daiichi Sankyo has challenged the Securities Appellate Tribunal (SAT) ju...

Ranbaxy Laboratories Monday said it would market products from Daiichi Sankyo`s portfolio in Mexico ...

Japan`s No.3 drugmaker Daiichi Sankyo said on Monday it would again delay its open offer for a 20 pe...

Japanese drug major Daiichi Sankyo said today a US Court has ruled in its favour in a patent litigat...

The Supreme Court on Friday allowed Japanese pharma firm Daiichi Sankyo to go ahead with the public ...